July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
August 2022 in “Case reports” Isotretinoin effectively treated a rare scalp condition, but careful drug monitoring and a dairy-free diet were important.
January 1988 in “Inpharma (Balgowlah)” New retinoids are effective for various skin conditions and are being developed to have fewer side effects.
18 citations
,
November 2018 in “Annals of the Academy of Medicine Singapore” Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
38 citations
,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
4 citations
,
August 2024 in “Skin Research and Technology”
11 citations
,
April 2020 in “Journal of Dermatological Treatment” Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.
1 citations
,
January 2025 in “Dermatologic Therapy” Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
213 citations
,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
November 2025 in “Journal of Pharmaceutical Research International” Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.
3 citations
,
September 2021 in “JAAD case reports” Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.
126 citations
,
October 1983 in “Journal of The American Academy of Dermatology” Isotretinoin effectively treats severe acne and similar conditions, but has common, mostly reversible side effects, requiring careful patient monitoring.
October 2024 in “Journal of the Endocrine Society” Type B Insulin Resistance Syndrome is rare, linked to lupus, and hard to treat due to severe insulin resistance.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
September 2024 in “Вопросы современной педиатрии” Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
December 2017 in “The Sri Lanka Journal of Dermatology” Infliximab successfully treated a severe hair loss case in Sri Lanka.
Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.